The benefits of Awareness, Trial, and Usage tracking can be enhanced if technology is introduced to bring responsiveness – and insights – in real time, as the business dictates.
As the US FDA moves towards issuing final guidelines on biosimilars, recent research with specialists in five main therapy areas suggests they are willing to embrace them if efficacy and safety
GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adu
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
